Atlético Madrid coach Diego Simeone was quizzed on Sunday by the media before he takes him to La Cartuja for a Monday night showdown with Real Betis. Simeone responded bluntly when he was questioned about how every bad result brings speculation…
Blog
-

Cardiovascular research scientist says never ignore these 3 early warning signs of heart disease: ‘Swelling in feet or…’
Published on: Oct 26, 2025 07:47 pm IST
Heart disease often develops silently. Cardiovascular research scientist Dr James DiNicolantonio shares 3 subtle early warning signs everyone should know.
Continue Reading
-

A Closer Look at Qualys (QLYS) Valuation Following Recent Share Price Trends
Qualys (QLYS) shares are trending slightly higher so far this month, showing around a 1% positive return over the past week. This comes at a time when the broader technology sector continues to face market volatility. Investors are keeping an eye on valuation and trends after recent pullbacks.
See our latest analysis for Qualys.
Zooming out, Qualys’s share price has slipped nearly 8% year-to-date but still posts a positive 1-year total shareholder return of around 6%. This reflects a mix of investor caution and enduring belief in its growth story. The momentum has faded recently, although its longer-term track record highlights an ability to deliver for shareholders.
Curious what else savvy investors are discovering? This could be a perfect time to broaden your research with fast growing stocks with high insider ownership
With Qualys trading below its analyst price target and fundamentals showing steady growth, the key question now is whether the stock is undervalued and offering potential upside, or if the market has already priced in future gains.
The current narrative fair value for Qualys lands at $141, which is noticeably higher than its last closing price of $128.05. This gap highlights ongoing optimism about the company’s prospects and sets the foundation for the key thinking driving this estimate.
Adoption of Qualys’ new cloud-native risk operations center (ROC) and Agentic AI platform positions the company as a leading pre-breach risk management provider. It offers unified orchestration, automation, and remediation across both Qualys and non-Qualys data. This opens incremental greenfield opportunities and should support higher ARPU and expanded TAM, leading to durable revenue and earnings growth.
Read the complete narrative.
What exactly propels this bullish narrative? Behind the ambitious price target are bold expectations about rising average customer spend, new platform launches and growing demand from global organizations. Want to see how much future growth, profit expansion and technology innovation must deliver in reality to make these numbers stack up? Find out what the consensus is betting on and what needs to go right by reading the full breakdown.
Result: Fair Value of $141 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, rapid AI innovation and new pricing models could disrupt Qualys’s momentum if competitors advance more quickly in development or if customer adoption trends unexpectedly shift.
Find out about the key risks to this Qualys narrative.
Continue Reading
-

The Toyota Supra Officially Dies Early Next Year
Toyota has announced it will end Supra production next March, with 2026 being the car’s last model year. The automaker already introduced the Final Edition, which…
Continue Reading
-

Gauging Valuation After Recent Modest Gains in Autonomous Vehicle Tech
Aurora Innovation (AUR) shares have edged slightly higher recently, following a modest uptick of about 2% in the last day and smaller gains over the past week. Investors seem to be weighing the company’s performance during the month, as Aurora continues its work in autonomous vehicle technology.
See our latest analysis for Aurora Innovation.
Zooming out, Aurora Innovation’s 1-year share price return is still down double digits, while its three-year total shareholder return remains notably positive. After a recent stretch of modest gains, momentum is still searching for its footing as investors gauge the company’s long-term roadmap and evolving risk profile.
If Aurora’s recent moves have you reflecting on shifts across the sector, now is the perfect time to explore innovation on a broader scale through the See the full list for free.
With shares trading well below analyst price targets and impressive long-term gains in the rearview, investors now face a critical question: Is Aurora a bargain poised for growth, or is the market already factoring in its future potential?
At a price-to-book ratio of 4.8x, Aurora Innovation trades below its peer average of 5.9x based on this valuation measure. This suggests the stock is relatively more attractively priced compared to similar companies. With the last close at $5.15, this indicates the market is discounting Aurora relative to its book value more than its immediate peer group.
The price-to-book ratio compares a company’s market value to its net asset value. This metric is particularly relevant for asset-light and high-growth sectors like software and autonomous vehicles. For Aurora, this ratio reflects what investors are willing to pay for the company’s equity compared to the book value recorded on its balance sheet.
This valuation suggests investors may be skeptical about Aurora’s path to profitability or are discounting near-term challenges, despite the sector’s broader appetite for growth. However, the company’s price-to-book still remains higher than the US Software industry average of 4x. This signals the market may still be assigning a premium for its technology or future prospects relative to the average US software company, though less so compared to its closest peers.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Book of 4.8x (UNDERVALUED compared to peers)
However, continued net losses and uncertainty around the company’s path to profitability remain challenges that could weigh on future share performance.
Continue Reading
-

Integrating GLP-1 Therapy, Advancing CSU Care, and Expanding Access
GLP-1 Receptor Agonists and Psoriasis
According to Serota, dermatologists should recognize obesity as a chronic inflammatory condition that often exacerbates inflammatory skin diseases such as psoriasis. “If your patient is overweight or obese,…
Continue Reading
-

World’s First Private Space Station, Haven-1 sets world record
Long Beach, California, United State–Haven-1, developed by the American company
Vast, a single-module station designed to launch in May 2026 on a SpaceX Falcon 9 rocket and will support up to four astronauts for short-duration missions,…Continue Reading
-

Pneumococcal Conjugate Vaccines Reduces Incidence of Pneumonia for Children 2 Years and Under
Pneumococcal conjugate vaccines (PCV) reduced the incidence of pneumonia and improved levels of IgG antibodies in pediatric patients, according to results of a study published in Frontiers in Pediatrics. However, there is a lack of data on…
Continue Reading
-

Google’s Gemini will now generate presentations for you
Google is rolling out out a new feature for Gemini’s Canvas, the free interactive workspace inside the AI chatbot’s app, meant for students and employees who need to create presentations. Gemini is now capable of generating slides with just a…
Continue Reading

